Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXGN AxoGen	$9.75 -2.9%	$13.40	$6.59 ▼ $21.00	$444.05M	1.05	477,861 shs	559,284 shs
KIDS OrthoPediatrics	$21.16 -2.6%	$21.51	$19.52 ▼ $35.99	$513.91M	1.08	200,055 shs	108,387 shs
LUNG Pulmonx	$3.03 -3.5%	$3.94	$2.83 ▼ $9.37	$126.41M	0.52	315,878 shs	179,455 shs
NPCE NeuroPace	$11.07 -1.4%	$12.87	$5.45 ▼ $18.98	$363.09M	2.03	169,089 shs	503,404 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXGN AxoGen	-2.89%	-10.71%	-17.51%	-43.48%	+20.97%
KIDS OrthoPediatrics	-2.58%	-0.14%	-7.40%	-15.63%	-32.74%
LUNG Pulmonx	-3.50%	-4.42%	-7.06%	-59.71%	-55.38%
NPCE NeuroPace	-1.42%	-15.82%	-29.04%	+3.55%	+59.28%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXGN AxoGen	2.6464 of 5 stars	3.5	2.0	0.0	2.7	2.5	0.6
KIDS OrthoPediatrics	4.3501 of 5 stars	3.4	2.0	3.9	2.8	4.2	0.6
LUNG Pulmonx	3.656 of 5 stars	3.3	5.0	0.0	2.0	3.3	1.3
NPCE NeuroPace	3.7262 of 5 stars	3.4	5.0	0.0	2.5	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXGN AxoGen	3.00	Buy	$22.20	127.69% Upside
KIDS OrthoPediatrics	2.83	Moderate Buy	$35.83	69.34% Upside
LUNG Pulmonx	2.63	Moderate Buy	$11.53	280.36% Upside
NPCE NeuroPace	2.83	Moderate Buy	$15.50	40.02% Upside

Current Analyst Ratings Breakdown

Latest LUNG, AXGN, KIDS, and NPCE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	NPCE NeuroPace	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$18.00
5/22/2025	LUNG Pulmonx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$6.50 ➝ $4.15
5/14/2025	NPCE NeuroPace	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$14.00 ➝ $16.00
5/14/2025	NPCE NeuroPace	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$17.00 ➝ $17.00
5/13/2025	AXGN AxoGen	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$26.00 ➝ $24.00
5/8/2025	KIDS OrthoPediatrics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $30.00
5/8/2025	KIDS OrthoPediatrics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
5/1/2025	LUNG Pulmonx	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $15.00
5/1/2025	LUNG Pulmonx	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$10.00 ➝ $9.00
5/1/2025	LUNG Pulmonx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $17.00
4/11/2025	KIDS OrthoPediatrics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$26.00 ➝ $24.00

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXGN AxoGen	$194.52M	2.28	N/A	N/A	$2.22 per share	4.39
KIDS OrthoPediatrics	$212.45M	2.42	N/A	N/A	$16.14 per share	1.31
LUNG Pulmonx	$87.47M	1.39	N/A	N/A	$3.09 per share	0.98
NPCE NeuroPace	$84.31M	4.31	N/A	N/A	$0.79 per share	14.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXGN AxoGen	-$21.72M	-$0.15	N/A	N/A	N/A	-7.91%	-14.91%	-7.49%	8/14/2025 (Estimated)
KIDS OrthoPediatrics	-$20.97M	-$1.75	N/A	N/A	N/A	-15.00%	-5.78%	-4.80%	8/4/2025 (Estimated)
LUNG Pulmonx	-$60.84M	-$1.44	N/A	N/A	N/A	-67.31%	-55.36%	-33.53%	7/30/2025 (Estimated)
NPCE NeuroPace	-$32.96M	-$0.84	N/A	N/A	N/A	-36.74%	-205.41%	-28.29%	8/12/2025 (Estimated)

Latest LUNG, AXGN, KIDS, and NPCE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	NPCE NeuroPace	-$0.26	-$0.21	+$0.05	-$0.21	$21.85 million	$22.52 million
5/7/2025	Q1 2025	KIDS OrthoPediatrics	-$0.26	-$0.39	-$0.13	-$0.46	$51.68 million	$52.41 million
5/7/2025	Q1 2025	LUNG Pulmonx	-$0.37	-$0.36	+$0.01	-$0.36	$22.03 million	$22.54 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXGN AxoGen	N/A	N/A	N/A	N/A	N/A
KIDS OrthoPediatrics	N/A	N/A	N/A	N/A	N/A
LUNG Pulmonx	N/A	N/A	N/A	N/A	N/A
NPCE NeuroPace	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXGN AxoGen	0.67	3.74	2.47
KIDS OrthoPediatrics	0.19	7.17	3.68
LUNG Pulmonx	0.40	7.70	6.77
NPCE NeuroPace	6.03	5.59	4.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXGN AxoGen	80.29%
KIDS OrthoPediatrics	69.05%
LUNG Pulmonx	91.04%
NPCE NeuroPace	78.83%

Insider Ownership

Company	Insider Ownership
AXGN AxoGen	2.78%
KIDS OrthoPediatrics	32.70%
LUNG Pulmonx	6.80%
NPCE NeuroPace	22.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXGN AxoGen	450	45.54 million	40.93 million	Optionable
KIDS OrthoPediatrics	200	24.29 million	16.52 million	Optionable
LUNG Pulmonx	250	40.26 million	37.24 million	Optionable
NPCE NeuroPace	170	32.80 million	23.22 million	Optionable

LUNG, KIDS, AXGN, and NPCE Headlines

Recent News About These Companies

NeuroPace’s SWOT analysis: med tech stock poised for growth amid challenges

June 14 at 10:03 AM | investing.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE

June 13 at 10:15 AM | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Shareholders to Connect

June 13 at 10:00 AM | accessnewswire.com

Potential Securities Fraud: Levi & Korsinsky Investigates NeuroPace, Inc. (NPCE)

June 12 at 10:30 AM | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against NeuroPace, Inc. (NPCE) And Encourages Shareholders to Reach Out

June 12 at 10:00 AM | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE

June 12 at 9:00 AM | prnewswire.com

Cantor Fitzgerald Weighs in on NeuroPace FY2026 Earnings

June 12 at 2:49 AM | americanbankingnews.com

Potential Securities Fraud: Levi & Korsinsky Investigates NeuroPace, Inc. (NPCE)

June 11 at 10:25 AM | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against NeuroPace, Inc. (NPCE) and Encourages Shareholders to Learn More About the Investigation

June 11 at 10:00 AM | accessnewswire.com

Fraud Investigation: Levi & Korsinsky Investigates NeuroPace, Inc. (NPCE) on Behalf of Shareholders

June 11 at 9:30 AM | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE

June 11 at 9:00 AM | accessnewswire.com

Two Sigma Investments LP Makes New Investment in NeuroPace, Inc. (NASDAQ:NPCE)

June 11 at 3:27 AM | marketbeat.com

NPCE ALERT: Ongoing Investigation Into NeuroPace, Inc. - Contact Levi & Korsinsky

June 10, 2025 | accessnewswire.com

NeuroPace, Inc. (NPCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

June 10, 2025 | accessnewswire.com

Cantor Fitzgerald Comments on NeuroPace FY2026 Earnings

June 10, 2025 | marketbeat.com

Levi & Korsinsky Investigates NeuroPace, Inc. (NPCE) Over Possible Securities Fraud

June 9, 2025 | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE

June 9, 2025 | accessnewswire.com

Did NeuroPace, Inc. (NPCE) Mislead Investors? Levi & Korsinsky Investigates

June 9, 2025 | accessnewswire.com

NeuroPace, Inc. (NPCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

June 9, 2025 | accessnewswire.com

Q2 Earnings Forecast for NeuroPace Issued By Leerink Partnrs

June 9, 2025 | marketbeat.com

Levi & Korsinsky Investigates NeuroPace, Inc. (NPCE) Over Possible Securities Fraud

June 8, 2025 | accessnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUNG, KIDS, AXGN, and NPCE Company Descriptions

AxoGen NASDAQ:AXGN

$9.75 -0.29 (-2.89%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$10.01 +0.26 (+2.67%)

As of 06/13/2025 07:09 PM Eastern

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

OrthoPediatrics NASDAQ:KIDS

$21.16 -0.56 (-2.58%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$21.16 0.00 (-0.02%)

As of 06/13/2025 04:04 PM Eastern

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediguard, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIMTM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIROTM Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, and Mitchell Ponseti. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.

Pulmonx NASDAQ:LUNG

$3.03 -0.11 (-3.50%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$3.06 +0.03 (+0.83%)

As of 06/13/2025 07:33 PM Eastern

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

NeuroPace NASDAQ:NPCE

$11.07 -0.16 (-1.42%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$11.10 +0.03 (+0.27%)

As of 06/13/2025 07:49 PM Eastern

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time